Walleye Trading LLC Revance Therapeutics, Inc. Call Options Transaction History

Walleye Trading LLC

15 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 15, 2024	SELL	$4.65 - $9.31 $58,125 - $116,375	-12,500 Reduced 47.53%	13,800 $67,000
Q4 2023 Feb 14, 2024	BUY	$5.81 - $11.2 $106,904 - $206,080	18,400 Added 232.91%	26,300 $231,000
Q3 2023 Nov 14, 2023	SELL	$11.47 - $25.07 $118,141 - $258,221	-10,300 Reduced 56.59%	7,900 $90,000
Q2 2023 Aug 14, 2023	BUY	$24.7 - $37.61 $190,190 - $289,597	7,700 Added 73.33%	18,200 $460,000
Q1 2023 May 15, 2023	SELL	$18.36 - $35.27 $227,664 - $437,348	-12,400 Reduced 54.15%	10,500 $338,000
Q4 2022 Feb 14, 2023	BUY	$18.32 - $30.66 $340,752 - $570,276	18,600 Added 432.56%	22,900 $422,000
Q3 2022 Nov 14, 2022	SELL	$14.33 - $28.47 $67,351 - $133,809	-4,700 Reduced 52.22%	4,300 $116,000
Q2 2022 Aug 08, 2022	BUY	$11.52 - $20.4 $100,224 - $177,480	8,700 Added 2900.0%	9,000 $124,000
Q1 2022 May 16, 2022	SELL	$12.36 - $20.31 $100,116 - $164,511	-8,100 Reduced 96.43%	300 $6,000
Q4 2021 Feb 14, 2022	SELL	$12.46 - $27.87 $58,562 - $130,989	-4,700 Reduced 35.88%	8,400 $137,000
Q3 2021 Nov 15, 2021	BUY	$25.78 - $33.21 $180,460 - $232,470	7,000 Added 114.75%	13,100 $365,000
Q2 2021 Aug 16, 2021	BUY	$26.8 - $31.84 $163,480 - $194,224	6,100 New	6,100 $181,000
Q1 2021 May 17, 2021	SELL	$24.03 - $29.97 $38,448 - $47,952	-1,600 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$23.41 - $28.34 $149,824 - $181,376	-6,400 Reduced 80.0%	1,600 $45,000
Q3 2020 Nov 16, 2020	BUY	$23.23 - $34.3 $185,840 - $274,400	8,000 New	8,000 $201,000

234

82.8M

680K

896K

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

Get notified when there are updates to the investment portfolio of Walleye Trading LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Trading LLC with notifications on news.